A Scottish biotech firm is set to accelerate clinical trials of its innovative stem cells therapy technology after being snapped up by London-based Precious Cells Group.
The deal for Pharmacells the first company to move into the BioCity Scotland campus will see 12 jobs created at the firm’s Newhouse base as well as a number of additional posts in the UK capital.
PCG’s interest in Pharmacells came from its patented Oristem stem cell harvesting and storage technology, which allows for an individual’s own cells to be used in their treatment.
The new investment brought by the PCG deal is expected to allow Pharmacells to push forward into full clinical trials.
